By Colin Kellaher
Eli Lilly on Thursday said a pair of late-stage studies of its proposed once-weekly insulin efsitora alfa met their primary endpoints.
The Indianapolis drugmaker said efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally in the Phase 3 studies in adults with type 2 diabetes using insulin for the first time and those who require multiple daily injections.
Eli Lilly said efsitora was safe and well-tolerated in both studies, adding that it expects topline readouts from three additional trials later this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
05-16-24 0734ET